Alvogen Korea
23
0
0
18
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
4.3%
1 terminated/withdrawn out of 23 trials
94.7%
+8.2% vs industry average
30%
7 trials in Phase 3/4
0%
0 of 18 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (23)
Phase IV Study of Qsymia in Obese Patients
Role: lead
AK-R215 Pharmacokinetic Study Phase I
Role: lead
DP-R213 Phase 1 Pharmacokinetics Study
Role: lead
Clinical Trial to Evaluate the Efficacy and Safety of DP-R212
Role: lead
A Phase 1 Drug Drug Interaction Clinical Trial of C1-R215 and C2-R215 in Healthy Male Volunteers
Role: lead
Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R208 and Each Monotherapy
Role: lead
Clinical Trial to Evaluate Efficacy and Safety of DP-R202 and Anplag in Patients With Artery Occlusive Disease
Role: lead
Safety and Pharmacokinetic Characteristics of DP-R206 in Healthy Adult Volunteers
Role: lead
Safety and Pharmacokinetic Characteristics of DP-R206(Vitamin D3) in Healthy Adult Volunteers
Role: lead
Phase III Clinical Trial of DP-R206 and Bonvia In Postmenopausal Women With Osteoporosis
Role: lead
DP-R213 Pharmacokinetics Study
Role: lead
DP-R212 Pharmacokinetic Study Phase I
Role: lead
DP-R208 Pharmacokinetic Study
Role: lead
DP-R212 Pharmacokinetic Study
Role: lead
A Study to Compare the Pharmacokinetics of DP-R207 in Comparison to Each Component Administered Alone
Role: lead
Isobide Solution and Meniace Tablets Compared to Monotherapy With Meniace Tablets
Role: lead
Clinical Trial to Compare the Pharmacokinetics of DP-R208
Role: lead
A Drug-drug Interaction Study of DP-R213
Role: lead
Efficacy/Safety of DP-R207 Tablet Versus CRESTOR Tablet in Patients With Primary Hypercholesterolemia
Role: lead
Pharmacokinetic Drug Interaction Between Candesartan and Rosuvastatin
Role: lead